CymaBay Therapeutics Inc (NASDAQ:CBAY) – Analysts at SunTrust Banks issued their Q1 2019 EPS estimates for shares of CymaBay Therapeutics in a research report issued on Wednesday, November 7th, according to Zacks Investment Research. SunTrust Banks analyst E. Nash expects that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter. SunTrust Banks also issued estimates for CymaBay Therapeutics’ Q2 2019 earnings at ($0.35) EPS, Q3 2019 earnings at ($0.37) EPS and Q4 2019 earnings at ($0.34) EPS.
Several other brokerages have also recently commented on CBAY. BidaskClub raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a research report on Thursday, August 9th. Oppenheimer set a $20.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Friday, October 5th. Finally, Zacks Investment Research raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, November 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $21.75.
Shares of NASDAQ:CBAY traded down $0.10 during mid-day trading on Monday, reaching $8.65. 598,700 shares of the stock were exchanged, compared to its average volume of 830,776. CymaBay Therapeutics has a one year low of $7.37 and a one year high of $15.59. The company has a market cap of $520.09 million, a PE ratio of -10.89 and a beta of 1.83.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04).
In other CymaBay Therapeutics news, CEO Sujal Shah acquired 5,000 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was bought at an average cost of $9.90 per share, with a total value of $49,500.00. Following the completion of the transaction, the chief executive officer now directly owns 100,000 shares in the company, valued at approximately $990,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 4.50% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CBAY. Baker BROS. Advisors LP lifted its holdings in CymaBay Therapeutics by 25.5% during the 2nd quarter. Baker BROS. Advisors LP now owns 4,917,700 shares of the biopharmaceutical company’s stock worth $65,996,000 after purchasing an additional 1,000,000 shares during the last quarter. BlackRock Inc. lifted its holdings in CymaBay Therapeutics by 9.5% during the 3rd quarter. BlackRock Inc. now owns 4,438,828 shares of the biopharmaceutical company’s stock worth $49,184,000 after purchasing an additional 384,543 shares during the last quarter. Redmile Group LLC lifted its holdings in CymaBay Therapeutics by 1.2% during the 3rd quarter. Redmile Group LLC now owns 2,993,565 shares of the biopharmaceutical company’s stock worth $33,169,000 after purchasing an additional 35,800 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in CymaBay Therapeutics by 37.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 2,844,766 shares of the biopharmaceutical company’s stock worth $31,520,000 after purchasing an additional 781,700 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in CymaBay Therapeutics by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,789,188 shares of the biopharmaceutical company’s stock worth $30,903,000 after purchasing an additional 109,989 shares during the last quarter. 94.57% of the stock is owned by institutional investors.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Recommended Story: What are municipal bonds?
Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com